KAPA Stock Chart & Stats
$0.61
-$0.43(-28.67%)
At close: 4:00 PM EST
$0.61
-$0.43(-28.67%)
Day’s Range― - ―
52-Week Range$0.33 - $2.11
Previous CloseN/A
Volume680.77K
Average Volume (3M)1.08M
Market Cap
$7.92M
Enterprise Value$6.11M
Total Cash (Recent Filing)$3.67M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding21,411,198
10 Day Avg. Volume532,234
30 Day Avg. Volume1,076,746
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.06
Price to Sales (P/S)0.00
P/FCF Ratio-3.80
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit76.37
Enterprise Value/Ebitda-1.08
Forecast
1Y Price Target
$12.00Price Target Upside1867.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.38
Revenue Forecast (FY)N/A
Kairos Pharma, Ltd. News
KAPA FAQ
What was Kairos Pharma, Ltd.’s price range in the past 12 months?
Kairos Pharma, Ltd. lowest stock price was $0.33 and its highest was $2.11 in the past 12 months.
What is Kairos Pharma, Ltd.’s market cap?
Kairos Pharma, Ltd.’s market cap is $7.92M.
When is Kairos Pharma, Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kairos Pharma, Ltd.’s earnings last quarter?
Currently, no data Available
Is Kairos Pharma, Ltd. overvalued?
According to Wall Street analysts Kairos Pharma, Ltd.’s price is currently Undervalued.
Does Kairos Pharma, Ltd. pay dividends?
Kairos Pharma, Ltd. does not currently pay dividends.
What is Kairos Pharma, Ltd.’s EPS estimate?
Kairos Pharma, Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kairos Pharma, Ltd. have?
Kairos Pharma, Ltd. has 21,411,198 shares outstanding.
What happened to Kairos Pharma, Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kairos Pharma, Ltd.?
Currently, no hedge funds are holding shares in KAPA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kairos Pharma, Ltd.
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
KAPA Stock 12 Month Forecast
Average Price Target
$12.00
▲(1867.21% Upside)
Technical Analysis
Ownership Overview
35.51% Insiders
1.40% Mutual Funds
0.21% Other Institutional Investors
62.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---








